Tao Liu

About

Tao Liu is a Biomedical Scientist VI in the Biological Sciences Division at PNNL. His research focuses on development and application of advanced MS technologies for post-translational modification, single-cell, spatial, and multi-omic characterization of cancers, leading to improved understanding of aberrant regulatory and signal transduction networks underlying cancers, as well as cancer biomarker discovery and verification. He is the principal investigator of several large-scale cancer research programs, such as the NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) and Early Detection Research Network (EDRN), and the DOD’s Framingham and PROMETHEUS projects as part of the Cancer Moonshot.

Employment

• Pacific Northwest National Laboratory Sr. Staff Scientist
  2005 - Present
• Pacific Northwest National Laboratory Postdoctoral Research Associate
  2003 - 2005
• University of Washington Howard Hughes Medical Institute Postdoctoral Research Associate
  2001 - 2003

Education

• Institute of Biochemistry and Cell Biology Biochemistry and Molecular Biology, Ph.D.
  1996 - 2001
• Nanchang University Chemistry, B.S.
  1992 - 1996

Projects & Funding

• Center for Advanced Multi-Omic Characterization of Cancer National Cancer Institute
  2022 - 2027
• PNNL Proteome Characterization Center National Cancer Institute
  2016 - 2022

Publications (193)

• Integrating data-dependent and data-independent acquisition methods for comprehensive lipidomic profiling using ion mobility spectrometry-mass spectrometry and a streamlined data analysis workflow
  Communications Chemistry 2026 DOI: 10.1038/s42004-026-02164-7
  +Save
• Data from MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia
  2026 DOI: 10.1158/2643-3230.c.8568738
  +Save
• Figure S1 from MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia
  2026 DOI: 10.1158/2643-3230.32845443
  +Save
• Figure S2 from MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia
  2026 DOI: 10.1158/2643-3230.32845440
  +Save
• Figure S3 from MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia
  2026 DOI: 10.1158/2643-3230.32845437
  +Save
• Figure S4 from MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia
  2026 DOI: 10.1158/2643-3230.32845434
  +Save
• MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia
  Blood Cancer Discovery 2026 DOI: 10.1158/2643-3230.BCD-25-0446
  +Save
• Supplementary Table S1 from MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia
  2026 DOI: 10.1158/2643-3230.32845431
  +Save
• Repurposing the liquid-based Pap test for the detection of ovarian cancer protein biomarkers.
  Clinical proteomics 2026 DOI: 10.1186/s12014-026-09610-7
  +Save
• Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.
  Nature cancer 2026 DOI: 10.1038/s43018-026-01175-6
  +Save
• Assessing current capabilities for incorporating lipidomics in multiomics data integration.
  Briefings in bioinformatics 2026 DOI: 10.1093/bib/bbag276
  +Save
• Molecular pathways for learning in the single-cell Stentor coeruleus.
  Current biology : CB 2026 DOI: 10.1016/j.cub.2026.03.080
  +Save
• A 15-layer multi-omics analysis of gastric cancer ecotypes provides therapeutic insights.
  Cell reports. Medicine 2026 DOI: 10.1016/j.xcrm.2026.102756
  +Save
• Assessing current capabilities for incorporating lipidomics in multiomics data integration
  2026 DOI: 10.26434/chemrxiv-2026-rkm55
  +Save
• Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.
  Cancer cell 2025 DOI: 10.1016/j.ccell.2025.07.011
  +Save
• The evolution of analytical techniques for multiplex analysis of protein biomarkers
  Expert Review of Proteomics 2025 DOI: 10.1080/14789450.2025.2529185
  +Save
• Proteomic-based stemness score measures oncogenic dedifferentiation and enables the identification of druggable targets.
  Cell genomics 2025 DOI: 10.1016/j.xgen.2025.100851
  +Save
• Precision proteogenomics reveals pan-cancer impact of germline variants.
  Cell 2025 DOI: 10.1016/j.cell.2025.03.026
  +Save
• Long-read RNA sequencing atlas of human microglia isoforms elucidates disease-associated genetic regulation of splicing.
  Nature genetics 2025 DOI: 10.1038/s41588-025-02099-0
  +Save
• Robust collection and processing for label-free single voxel proteomics.
  Nature communications 2025 DOI: 10.1038/s41467-024-54643-x
  +Save